MMAI Model More Accurately Predicts Outcomes of High-Risk Prostate Cancer
An MMAI model can accurately predict long-term outcomes in patients with high-risk prostate cancer, a study suggests.
Genitourinary Cancers Symposium
nsRPLND Appears Safe, Effective in Low-Volume Metastatic Seminoma
Nerve-sparing retroperitoneal lymph node dissection appears safe and effective for patients with low-volume metastatic seminoma.
New Model Better Predicts Relapse in Stage I Seminoma
A new risk stratification model can identify patients with stage I seminoma who have a high risk of relapse, according to researchers.
Talabostat Plus Pembrolizumab Exhibits Activity in mCRPC With SCNC Phenotype
Combination talabostat and pembrolizumab has shown antitumor activity in patients who have metastatic castration-resistant prostate cancer with small-cell neuroendocrine carcinoma phenotype.
Imaging With 89Zr-DFO-Girentuximab Identifies Clear Cell Renal Cell Carcinoma
A novel imaging technique, 89Zr-DFO-girentuximab PET/CT, can accurately and noninvasively identify clear cell renal cell carcinoma, a study suggests.
Combo Shows Promise in High-Risk nmCRPC
Treatment with radiolabeled J591 plus ketoconazole and hydrocortisone may delay time to metastasis in patients with high-risk nmCRPC.
Cabozantinib Shows Activity in Advanced RCC After CPI-Based Combinations
Cabozantinib can produce responses in patients with advanced clear cell RCC whose disease progressed on first-line checkpoint inhibitor-based therapy, a phase 2 study suggests.
Pembrolizumab Could Meet Unmet Need in BCG-Unresponsive High-Risk NMIBC
Pembrolizumab demonstrated antitumor activity in patients with high-risk, papillary NMIBC who did not undergo radical cystectomy and did not respond to BCG.
Sacituzumab Govitecan Elicits Responses in Platinum-Ineligible Metastatic Urothelial Carcinoma
Sacituzumab govitecan has demonstrated activity in patients with platinum-ineligible metastatic urothelial carcinoma whose disease progressed after checkpoint inhibitor therapy.
TALAPRO-2: Talazoparib Improves rPFS in Metastatic Castration-Resistant Prostate Cancer
Adding talazoparib to first-line treatment with enzalutamide improves radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer, results of the TALAPRO-2 trial suggest.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Genitourinary Cancers Symposium
Loading... 
Loading...